Development of a dual-functional conjugate of antigenic peptide and Fc-III mimetics (DCAF) for targeted antibody blocking

Abstract

Long peptide DCAF enables high selectivity to target harmful antibodies, providing new thoughts for antibody-induced disease intervention.

Nanodisc‐Mediated Conversion of Virustatic Antiviral Antibody to Disrupt Virus Envelope in Infected Cells

“…Furthermore, Fc‐III has been employed in a variety of studies to attach nanoparticles, proteins, and small molecules to antibody. [ 29 ] Although off‐rate constant between Fc‐III with IgG1 predicts a half‐life of several minutes, efficient delivery of cargo molecules to target sites in previous studies supports Fc‐III‐mediated conjugation to IgG1 is likely maintained during circulation. The one‐pass circulation time of blood in a mouse has been determined to be approximately 15 s. [ 30 ]…”

“…Fc‐III, a 13‐mer peptide, enables proteins bind to human IgG with a binding constant of 16 n m , [ 21 ] but not to mouse or rat IgG isotypes. [ 29 ] Fc‐III has been shown to endow a fluorescence protein with a long circulation half‐life of ≈8 h in mice, a 75‐fold increase compared to unmodified fluorescence protein when it is administered with human IgG. Furthermore, Fc‐III has been employed in a variety of studies to attach nanoparticles, proteins, and small molecules to antibody.…”

Antibody dependent enhancement: Unavoidable problems in vaccine development

“…Zhang made specific antigen peptides, linkers and Fc-III mimetic peptides into Dual-functional Conjugate of Antigenic peptide and Fc-III tag(DCAF) ( Zhang et al, 2019 ). The Fc-III part inhibited the dengue fever ADE process to a certain extent and blocked the antibodies-Virus or antibody-Fc receptor interaction.…”